Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
01 1Aarti Pharmalabs Limited
02 1Wavelength Enterprises LTD
03 1Dr. Reddy's Laboratories Limited
04 1Assia Chemical Industries Ltd. - Teva Tech Site
05 1Catalent Micron Technologies, Inc.
06 1Hetero Labs Limited
07 1Lonza Guangzhou Pharmaceutical Ltd.
08 4MSN Laboratories Private Limited
09 1Natco Pharma Limited
10 1SHILPA PHARMA LIFESCIENCES LIMITED
11 2ScinoPharm Taiwan Ltd.
01 2IBRUTINIB
02 6Ibrutinib
03 1Ibrutinib (Form-A)
04 1Ibrutinib (Form-C)
05 1Ibrutinib (Form-M5)
06 1Ibrutinib HFCC
07 1Ibrutinib(Amorphous)
08 1Ibutinib
09 1ibrutinib
01 1France
02 9India
03 1Israel
04 2Taiwan
05 2U.S.A
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
NDC Package Code : 15308-2402
Start Marketing Date : 2024-01-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (200kg/200kg)
Marketing Category : BULK INGREDIENT
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
NDC Package Code : 58175-0602
Start Marketing Date : 2014-12-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 71796-053
Start Marketing Date : 2022-11-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63415-0531
Start Marketing Date : 2022-11-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 40006-040
Start Marketing Date : 2012-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0046
Start Marketing Date : 2016-05-23
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0049
Start Marketing Date : 2016-07-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0082
Start Marketing Date : 2018-11-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0102
Start Marketing Date : 2020-09-05
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63850-8089
Start Marketing Date : 2020-01-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
A Ibrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ibrutinib, including repackagers and relabelers. The FDA regulates Ibrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ibrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ibrutinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ibrutinib supplier is an individual or a company that provides Ibrutinib active pharmaceutical ingredient (API) or Ibrutinib finished formulations upon request. The Ibrutinib suppliers may include Ibrutinib API manufacturers, exporters, distributors and traders.
click here to find a list of Ibrutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ibrutinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ibrutinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ibrutinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ibrutinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ibrutinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ibrutinib suppliers with NDC on PharmaCompass.
We have 11 companies offering Ibrutinib
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
